Affimed N.V. (AFMD) Short-Term Debt to Capital
Affimed (AFMD) is developing cellular immunity regulators while optimizing supply chains to protect profits and reduce costs. Developments in the fight against lymphomas remain independent of market volatility, with the key metric standing at 0.00. The business relies on a stable workforce within the R&D sector. This chart provides a visual snapshot of the price action for specific debt and the company's short positions.
Metric breakdowns and analytics for Affimed Therapeutics (AFMD)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Comprehensive company analysis:Affimed N.V., AFMD
Due to the non-cyclical nature of immuno-oncology drug development, Affimed possesses high macro-resilience, while the current value of 0.00 reflects the proportion of short-term liabilities to own resources, allowing for an assessment of liquidity risk and the probability of capital loss during a trend reversal through an analysis of changes in short-term debt levels relative to equity.
Competing companies
Argenx (ARGX) - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital BioNTech Pharma (BNTX)|Short-Term Debt to Capital ABVX (Abivax Pharma)|admabiologics.com - Short-Term Debt to Capital|Short-Term Debt to Equity Protagonist (PTGX)|IMVT: Ratio of Short-Term Indebtedness to Capital|KNSA (Kiniksa Pharmaceuticals Ltd) - Short-Term Debt to Equity|Grifols Biemat (GRFS) - Short-Term Debt to Equity Ratio|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com (CLDX)|Aurinia Pharmaceuticals Inc. (AUPH) - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital BioCryst Pharmaceuticals, Inc. (BCRX)|Short-Term Debt to Capital VERA|Dianthus Corp - Short-Term Debt to Capital Coefficient|PHVS: Short-Term Debt to Equity|ABCL: Short-Term Debt to Equity Ratio|TRML (Tourmaline Bio) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|PHAR (Pharming) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital NKTR|Short-Term Debt to Equity Upstream Bio Inc UPB|Short-Term Debt to Capital Ratio zenasbio.com (ZBIO)|IMNM: Short-Term Debt to Capital|Current Liabilities to Capital Gossamer Bio Inc GOSS|KalVista Pharmaceuticals Inc - Short-Term Debt to Capital|SEPN - Short-Term Debt to Capital|Short-Term Debt to Capital Pieris Pharmaceuticals (PVLA)|savarapharma.com (SVRA) - Current Liabilities to Equity|Short-Term Debt to Capital Rigel Pharmaceuticals, Inc. RIGL|Current Liabilities to Equity AnaptysBio Inc|ATXS (Astria Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient ENGN (enGene Corp)|RAPT Therapeutics - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Aerovate Therapeutics, Inc. JBIO|ACRS (Aclaris Therapeutics, Inc.) - Short-Term Debt to Capital|KYTX - Current Liabilities to Capital|Short-Term Debt to Capital Tiziana Life Sciences PLC|Cabaletta Bio Inc (CABA) - Short-Term Debt to Capital Ratio|VTYX (Ventyx Biosciences) - Short-Term Debt to Capital|Short-Term Debt to Capital theratech.com|AVTX - Short-Term Debt to Capital|Current Liabilities to Equity ELDN (Eledon Pharmaceuticals Inc.)|Agenus Inc - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Climb Bio, Inc CLYM|Zura Bio (ZURA) - Short-Term Debt to Capital|ATYR: Short-Term Debt to Capital Ratio|Short-Term Debt to Equity adagene.com (ADAG)|Ikena Oncology (IMA) - Current Liabilities to Equity|STTK - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Equillium Bio|Short-Term Debt to Capital CNTB|Short-Term Debt to Capital IMUX (immunic-therapeutics.com)|Short-Term Debt to Equity Atara Bio|InflaRx NV - Ratio of Short-Term Indebtedness to Capital|XFOR: Short-Term Debt to Equity|ACET - Short-Term Debt to Equity Ratio|CELU: Short-Term Debt to Capital|Short-Term Debt to Capital inmunebio.com|BRNS - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Kezar Life Sciences Inc.|SABS (SAB Biotherapeutics, Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient AKTX (Akari Therapeutics, Plc)|Enlivex Therapeutics Ltd. - Short-Term Debt to Equity|Q32 Bio Inc - Short-Term Debt to Equity Ratio|GOVX: Short-Term Debt to Equity|Edesa Biotech Inc (EDSA) - Short-Term Debt to Equity Ratio|IBIO: Short-Term Debt to Equity Ratio|CARM (Carisma Therapeutics Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity XTL Biopharmaceuticals (XTLB)|Short-Term Debt to Capital Ratio Bolt Bio|HCW Biologics Inc. - Short-Term Debt to Capital|Current Liabilities to Capital aptevotherapeutics.com (APVO)|Short-Term Debt to Capital AIM (AIM ImmunoTech Inc.)|Short-Term Debt to Capital Aditxt Inc. ADTX|Short-Term Debt to Capital GRI Bio, Inc.|XRTX - Current Liabilities to Equity|Short-Term Debt to Capital Vyome Holdings (HIND)|Revelation Biosciences Inc (REVB) - Current Liabilities to Equity|INDP: Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient SCNI|Short-Term Debt to Equity CALI (CalciMedica, Inc.)|Short-Term Debt to Equity Ratio allakos.com (ALLK)|HOOK: Short-Term Debt to Capital|Current Liabilities to Capital IGM Biosciences Inc. IGMS|iTeos (ITOS) - Short-Term Debt to Capital|OCEA - Short-Term Debt to Capital Ratio|TCBP: Short-Term Debt to Capital|thirdharmonicbio.com (THRD) - Short-Term Debt to Capital